Nykode Therapeutics As

Greetings and welcome to the NICO Therapeutics third quarter 2024 conference call and webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may ask a question anytime by typing it into the ask a question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to your host, CEO, Michael Ensign. Please go ahead.

Thank you very much, Kevin, and a warm welcome to everybody this early hours of Scandinavia, to dial in from there. Go to the next slide here. I just want to remind everybody of our forward-looking statements. I assume you're familiar with the wording on that. On that note, we will move forward. I'm very pleased to have with me today here in the room Anita Frederiksen, Chief Scientific Officer and Business Development, Harald Gurvin, Chief Financial Officer, and today we also are pleased to have Martin Nikolson, the Chairman of the Board. And Martin, I'm going to hand over to you to kick us off this quarterly update for third quarter 2024.

Thank you, Michael, and welcome from my side as well. It's a pleasure to join you this morning. As announced this morning, NICOD is launching a new focused operating model, which the board of directors fully stands behind. Basically, it will mean that NICOD will transform into a leaner research and technology-driven organization. With our current strong cash position, NICODE aims to operate with a substantially reduced annual cost base of approximately 20 million US dollars, which will extend our cash runway into 2030. Put into context, NICODE will focus on advancing its unique vaccine body technology platform into innovative therapeutic modalities for which we intend to seek early-stage partnerships. For the existing clinical assets, VB1016 and now recently VB10Neo, NICODE will explore possibilities for partnerships. Hence, new pivotal clinical trials for these assets will only be conducted under potential partnership agreements. In summary, the Board believes This operating model is a balanced, cost-conscious way forward built on financial stability, extending our business into 2030. A timeframe sufficient enough to explore many commercially exciting therapeutic opportunities with our unique platform, which hopefully will attract external parties to enter partnerships with NICODE. With that, I hand over back to Michael, who will give you more details on this and, of course, to go through with his teammates the financial report for the third quarter. Over to you, Michael.